It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The outcome of CRISPR-Cas-mediated genome modifications is dependent on DNA double-strand break (DSB) processing and repair pathway choice. Homology-directed repair (HDR) of protein-blocked DSBs requires DNA end resection that is initiated by the endonuclease activity of the MRE11 complex. Using reconstituted reactions, we show that Cas9 breaks are unexpectedly not directly resectable by the MRE11 complex. In contrast, breaks catalyzed by Cas12a are readily processed. Cas9, unlike Cas12a, bridges the broken ends, preventing DSB detection and processing by MRE11. We demonstrate that Cas9 must be dislocated after DNA cleavage to allow DNA end resection and repair. Using single molecule and bulk biochemical assays, we next find that the HLTF translocase directly removes Cas9 from broken ends, which allows DSB processing by DNA end resection or non-homologous end-joining machineries. Mechanistically, the activity of HLTF requires its HIRAN domain and the release of the 3′-end generated by the cleavage of the non-target DNA strand by the Cas9 RuvC domain. Consequently, HLTF removes the H840A but not the D10A Cas9 nickase. The removal of Cas9 H840A by HLTF explains the different cellular impact of the two Cas9 nickase variants in human cells, with potential implications for gene editing.
Cas9 remains bound to DNA after cleavage and its removal is required for DNA double-strand break repair. Here, the authors show that the HLTF translocase disrupts the Cas9- DNA post-cleavage complexes in a process that requires the HLTF HIRAN domain and ATPase activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Università della Svizzera italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland (GRID:grid.29078.34) (ISNI:0000 0001 2203 2861)
2 Johns Hopkins University, Department of Biophysics & Biophysical Chemistry, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Stanford University School of Medicine, Department of Pathology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
3 Johns Hopkins University, Department of Biophysics, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Boston Children’s Hospital, Program in Cellular and Molecular Medicine, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438)
4 National Cancer Institute, NIH, Laboratory of Genome Integrity, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
5 University of Zurich, Winterthurerstrasse 190, Department of Biochemistry, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
6 Università della Svizzera italiana (USI), Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland (GRID:grid.29078.34) (ISNI:0000 0001 2203 2861); Plaksha University, Biological Systems Engineering, Mohali, India (GRID:grid.29078.34)
7 Institute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, CEA, CNRS, Gif-sur-Yvette, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
8 Johns Hopkins University, Department of Biophysics & Biophysical Chemistry, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Biophysics, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Boston Children’s Hospital, Program in Cellular and Molecular Medicine, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Pediatrics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Howard Hughes Medical Institute, Boston, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581)